VaxInnate Corporation’s License Agreement With Emergent BioSolutions Improves U.S. Preparedness for Potential Flu Pandemics

Published: Jan 16, 2013

CRANBURY, N.J.--(BUSINESS WIRE)--A license agreement for the manufacture and sale of VaxInnate Corporation’s recombinant flu vaccine by Emergent BioSolutions is a step toward helping the United States be better prepared in the event of an influenza pandemic. VaxInnate is a biotechnology firm pioneering breakthrough technology for the development of novel vaccines.

Back to news